A contract research organization (CRO) is an organization that offers a wide range of pharmaceutical research services that include drug discovery, process development, toxicology, clinical trial management and many more services.
Clients of NoAb BioDiscoveries are able to profile compounds for selection of the best candidates for further pre-clinical and clinical development as a result of in vivo and in vitro ADME/PK studies and gene expression assays.
Located in a 12,600 ft.² facility in Mississauga, Ontario, NoAb BioDiscoveries offers a wide range of drug discovery services, including in vivo and in vitro testing, bioanalytical services, DTEx technology and pharmacokinetic determinations.
NoAb BioDiscoveries' approach to HTS ADMET profiling includes a range of in vitro assays that have been skillfully designed and are performed by highly trained and experienced scientists under strict guidelines.
NoAb BioDiscoveries is a leading research facility located in the heart of one of North America's key biotech hubs and offers a wide range of specialized and proprietary research services that focus on lead selection and optimization in drug discovery research.
The human body is a strange thing that doctors are still trying to understand. Despite all the mysteries that are still being investigated everyday there are some parts that they have discovered are very useful for diagnosing a number of various problems or conditions.
The CYP inhibition assay at NoAb BioDiscoveries is available for nine of the enzymes that include CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 and is a fluorescent based assay.
Man will always be faced with disease and the need to discover new drugs is a constant battle for scientists especially since the process of identifying suitable drug candidates takes a long time.
NoAb BioDiscoveries continues on the path to delivering premier drug discovery services to its clients and ensuring their success by consistently developing advanced research tools to better characterize the pharmacokinetic properties of drug candidates, optimizing the selection of viable clinical candidates.
Drug Metabolism Pharmacokinetics
In drug discovery research it is vital to investigate the way a potential drug candidate molecule is absorbed, distributed, metabolized and excreted (ADME) in order to prevent a lot of time and money being spent on pharmaceutical compounds which are toxic to humans.
Medical technology has lead to the development of a number of very useful drugs. These drugs, or medicines as they are more popularly known, are used for the treatment of all sorts of illnesses and conditions that affect the human race.
Drug discovery research involves the study of the pharmacokinetics of new pharmaceutical compounds by investigating the absorption, distribution, metabolism and excretion (ADME) of the drug using both in vitro and in vivo assays.
Early ADME studies are an important part of drug discovery. The results of these studies are often used to identify the best drug candidates or shape the future development of pharmaceuticals.
As a cutting edge provider of specialized and proprietary research services that help to shape and optimize the drug discovery process, NoAb BioDiscoveries is continuously developing new and innovative technologies and tools that accelerate the timelines and achieve success.
These assays are continuously improved upon at NoAb BioDiscoveries using innovation to produce advanced research tools that better characterize the pharmacokinetic properties of new drug candidates, optimizing the selection of viable clinical candidates.
NoAb BioDiscoveries is a contract research organization located in the heart of one of North America's key biotech hubs that provides a wide range of specialized and proprietary research services for drug discovery research.
The scientists design the best strategies and protocols for any drug discovery need and skillfully perform standard and specialized procedures according to customer specifications.
A typical microdialysis study at the NoAb BioDiscoveries' research facility located in the heart of one of North America's key biotech hubs, involves the implantation of two dialysis probes: one into a specific brain area of interest and the other into the jugular vein.
Using specialized and proprietary research services that are continually being developed and improved upon, NoAb BioDiscoveries accelerates the drug development process to offer success and shorter timelines in the production of optimal and viable candidates.
NoAb BioDiscoveries provides a wide range of specialized in proprietary research services. All work conducted by the facility is carried out to be stricter standards, both scientific and ethical, ensuring the most reliable results.
Preclinical bioanalytical methods can be used to construct plasma concentration versus time profiles using chemical techniques that measure the concentration of the drug candidate in the biological matrix which is most often plasma.
All the studies are carried out at the preclinical CRO's research facility under strict guidelines that may not be GLP guidelines but are performed under the same spirit with the proper controls.
Using the information generated from the preclinical in vivo PK studies, in vitro ADME assays and other discovery services, clients are afforded the ability to profile compounds for the selection of the best candidates for further preclinical and clinical development.
Preclinical pharmacokinetics studies are performed at the NoAb BioDiscoveries' research facility which is located in the heart of one of North America's key biotech hubs.
Pharmacokinetics or PK is the study of what the body does to a drug when administered externally to a living organism and is divided into a number of areas including studying the extent of absorption, distribution, metabolism and excretion (ADME) of a pharmaceutical compound.
Evaluation of in vivo drug exposure is a vital component in the decision making process undertaken by drug discovery teams in determining the safety and efficiency of a particular drug.
